Creative Medical Technology Holdings Inc expected to post a loss of 52 cents a share - Earnings Preview
06/05/2025 21:03
Creative Medical Technology Holdings Inc CELZ.OQ CELZ.O is expected to show no change in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Creative Medical Technology Holdings Inc is for a loss of 52 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Creative Medical Technology Holdings Inc is $26.00, above its last closing price of $2.04. This summary was machine generated May 6 at 20:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM